Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hasford

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Leukemia|October 17, 2003
Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trialG Buesche, R Hehlmann, H Hecker, et al.
Leukemia|April 1, 1997
Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study GroupR Hehlmann, A Willer, H Heimpel, et al.
The Journal of Biological Chemistry|May 15, 2003
Formation of prostaglandins E2 and D2 via the isoprostane pathway: a mechanism for the generation of bioactive prostaglandins independent of cyclooxygenaseLing Gao, William E Zackert, Justin J Hasford, et al.
Leukemia|July 31, 2004
Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemiaG Buesche, M Freund, R Hehlmann, et al.
European Journal of Clinical Pharmacology|May 25, 2016
A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarctionA Afonso, S Schmiedl, C Becker, et al.
Leukemia|September 13, 2003
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alphaU Berger, G Engelich, O Maywald, et al.
Blood|March 21, 1998
Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study GroupR P Gale, R Hehlmann, M J Zhang, et al.
Respiratory Medicine|May 16, 2015
Seasonal changes in prescribing of long-acting beta-2-agonists-containing drugsM Rottenkolber, E Voogd, L van Dijk, et al.
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Bone Marrow Transplantation|May 1, 1996
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study GroupR Hehlmann, H Heimpel, D K Hossfeld, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Leukemia|October 17, 2003
Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trialG Buesche, R Hehlmann, H Hecker, et al.
Leukemia|April 1, 1997
Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study GroupR Hehlmann, A Willer, H Heimpel, et al.
The Journal of Biological Chemistry|May 15, 2003
Formation of prostaglandins E2 and D2 via the isoprostane pathway: a mechanism for the generation of bioactive prostaglandins independent of cyclooxygenaseLing Gao, William E Zackert, Justin J Hasford, et al.
Leukemia|July 31, 2004
Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemiaG Buesche, M Freund, R Hehlmann, et al.
European Journal of Clinical Pharmacology|May 25, 2016
A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarctionA Afonso, S Schmiedl, C Becker, et al.
Leukemia|September 13, 2003
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alphaU Berger, G Engelich, O Maywald, et al.
Blood|March 21, 1998
Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study GroupR P Gale, R Hehlmann, M J Zhang, et al.
Respiratory Medicine|May 16, 2015
Seasonal changes in prescribing of long-acting beta-2-agonists-containing drugsM Rottenkolber, E Voogd, L van Dijk, et al.
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Bone Marrow Transplantation|May 1, 1996
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study GroupR Hehlmann, H Heimpel, D K Hossfeld, et al.
Pageof 11